Kazia Therapeutics (Kazia Therapeutics) Change In Payables And Accrued Expense : $1.90 Mil (TTM As of Dec. 2023)

View and export this data going back to 1999. Start your Free Trial

What is Kazia Therapeutics Change In Payables And Accrued Expense?

Kazia Therapeutics's Change In Payables And Accrued Expense for the quarter that ended in Dec. 2023 was $1.11 Mil. It means Kazia Therapeutics's Accounts Payable & Accrued Expense increased by $1.11 Mil from Jun. 2023 to Dec. 2023 .

Kazia Therapeutics's Change In Payables And Accrued Expense for the fiscal year that ended in Jun. 2023 was $0.38 Mil. It means Kazia Therapeutics's Accounts Payable & Accrued Expense increased by $0.38 Mil from Jun. 2022 to Jun. 2023 .

Kazia Therapeutics Change In Payables And Accrued Expense Historical Data

The historical data trend for Kazia Therapeutics's Change In Payables And Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kazia Therapeutics Change In Payables And Accrued Expense Chart

Kazia Therapeutics Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Change In Payables And Accrued Expense

Get a 7-Day Free Trial

-0.28

1.19

0.77

-0.37

0.38

Kazia Therapeutics Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Change In Payables And Accrued Expense	Get a 7-Day Free Trial															1.15	-1.50	-0.41	0.79	1.11

Kazia Therapeutics Change In Payables And Accrued Expense Calculation

Change In Payables And Accrued Expense is the increase or decrease between periods of the Accounts Payable & Accrued Expense. Accrued expenses represent expenses incurred at the end of the reporting period but not yet paid; also called accrued liabilities. The accrued liability is shown under Liabilities section in the balance sheet.

Change In Payables And Accrued Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was $1.90 Mil.

Kazia Therapeutics Change In Payables And Accrued Expense Related Terms

Thank you for viewing the detailed overview of Kazia Therapeutics's Change In Payables And Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Kazia Therapeutics (Kazia Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kazia Therapeutics Ltd (NAS:KZIA) » Definitions » Change In Payables And Accrued Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

300 Barangaroo Avenue, Level 24, Three International Towers, Sydney, NSW, AUS, 2000

Website

https://www.kaziatherapeutics.com

Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing innovative anti-cancer drugs. The group is developing paxalisib, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. The company is also developing EVT801 for the treatment of various tumors.

Executives

Josiah T Austin	director, 10 percent owner	4673 CHRISTOPHER PLACE, DALLAS TX 75204
El Coronado Holdings, Llc	10 percent owner	4673 CHRISTOPHER PLACE, DALLAS TX 75204